Recombinant Human CCL13 Protein(Trx Tag)

SKU: PDEH100512

Size:100μg

Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping:This product is provided as lyophilized powder which is shipped with ice packs.

Exp date:12 months

Category ID_II:Recombinant Proteins

Category ID_III:Cytokines

Abbreviation:CCL13

Target Synonym:MCP;NCC;CCL;SCYA;MCP4;NCC1;SCYA13;CCL13;C-C motif chemokine 13;Chemokine (C C motif) ligand 13;CK beta 10;CKb10;CK-beta-10;MCP-4;MGC17134;Monocyte chemoattractant protein 4;Monocyte chemotactic protein 4;NCC 1;NCC-1;New CC chemokine 1;SCYL1;short chain;Small inducible cytokine A13 precursor;Small inducible cytokine subfamily A (Cys Cys) member 13;Small-inducible cytokine A13

Research Areas:Immunology;Signal Transduction;Neuroscience

Conjugation:

Target Species:Human

Expression Host:E.coli

Application:

Fusion tag:N-Trx

UNIProt ID:Q99616

Accession:Q99616

Background:Monocyte Chemoattractant Proteins 4 (MCP-4/CCL13) is a member of a distinct, structurally-related subclass of CC chemokines mainly involved in recruitment of eosinphils to inflammatory sites. CCL13/MCP-4, is a CC family chemokine that is chemoattractant for eosinophils, basophils, monocytes, macrophages, immature dendritic cells, and T cells, and its capable of inducing crucial immuno-modulatory responses through its effects on epithelial, muscular and endothelial cells. Similar to other CC chemokines, CCL13 binds to several chemokine receptors (CCR1, CCR2 and CCR3), allowing it to elicit different effects on its target cells. A number of studies have shown that CCL13 is involved in many chronic inflammatory diseases, in which it functions as a pivotal molecule involved in the selective recruitment of cell lineages to the inflamed tissues and their subsequent activation. MCP-4/CCL13 is secreted from chondrocytes and activates the proliferation of rheumatoid synovial cells, thereby leading to joint destruction in RA. The interferon-gamma in combination with interleukin-1beta/tumor necrosis factor-alpha activates the production of MCP-4/CCL13 from chondrocytes in RA joints, and that secreted MCP-4/CCL13 enhances fibroblast-like synoviocyte proliferation by activating the extracellular signal-regulated kinase mitogen-activated protein kinase cascade. CCL13 may have some role in the pathogenesis of systemic sclerosis (SSc).

Concentration:

Activity:Not validated for activity

Sequence:Gln24-Thr98

Purity:> 80% as determined by reducing SDS-PAGE.

Formulation:Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

Reconstitution:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis

Endotoxin:< 10 EU/mg of the protein as determined by the LAL method

Calculated MW:28.3 kDa

ObservedMW:31 kDa